Ocugen Inc Stock Today
| OCGN Stock | USD 0.54 0.04 6.90% |
PerformanceVery Weak
| Odds Of DistressLow
|
Ocugen is selling at 0.54 as of the 17th of March 2025; that is 6.9 percent decrease since the beginning of the trading day. The stock's open price was 0.58. Ocugen has less than a 14 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 17th of December 2024 and ending today, the 17th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 3rd of December 2014 | Category Healthcare | Classification Health Care |
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company has 292.01 M outstanding shares of which 60.26 M shares are now shorted by private and institutional investors with about 18.84 trading days to cover. More on Ocugen Inc
Moving together with Ocugen Stock
| 0.64 | VRCA | Verrica Pharmaceuticals | PairCorr |
| 0.79 | ENVB | Enveric Biosciences Earnings Call This Week | PairCorr |
| 0.65 | EVO | Evotec SE ADR | PairCorr |
Moving against Ocugen Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Ocugen Stock Highlights
| CEO CoFounder | Shankar MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsOcugen can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Ocugen's financial leverage. It provides some insight into what part of Ocugen's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ocugen Inc (OCGN) is traded on NASDAQ Exchange in USA. It is located in 11 Great Valley Parkway, Malvern, PA, United States, 19355 and employs 95 people. Ocugen is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 156.9 M. Ocugen Inc conducts business under Biotechnology sector and is part of Health Care industry. The entity has 292.01 M outstanding shares of which 60.26 M shares are now shorted by private and institutional investors with about 18.84 trading days to cover.
Ocugen Inc currently holds about 101.6 M in cash with (42.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.46.
Check Ocugen Probability Of Bankruptcy
Ownership AllocationOcugen owns a total of 292.01 Million outstanding shares. Roughly 73.91 pct. of Ocugen outstanding shares are held by general public with 1.27 % owned by insiders and only 24.82 (%) by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Ocugen Ownership Details
Ocugen Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Ci Private Wealth Llc | 2024-12-31 | 900.1 K | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 860.2 K | |
| Goldman Sachs Group Inc | 2024-12-31 | 825.8 K | |
| Nuveen Asset Management, Llc | 2024-12-31 | 756.9 K | |
| Bank Of New York Mellon Corp | 2024-12-31 | 545.2 K | |
| Wellington Management Company Llp | 2024-12-31 | 507.5 K | |
| Jane Street Group Llc | 2024-12-31 | 496.2 K | |
| Group One Trading, Lp | 2024-12-31 | 466.3 K | |
| Barclays Plc | 2024-12-31 | 453.4 K | |
| Blackrock Inc | 2024-12-31 | 19.9 M | |
| Vanguard Group Inc | 2024-12-31 | 16.6 M |
Ocugen Historical Income Statement
Ocugen Stock Against Markets
Ocugen Corporate Management
| Durgaprasad Annavajjula | Head VP | Profile | |
| CPA CPA | Sr Officer | Profile | |
| CMA CPA | Chief Officer | Profile | |
| Michael Shine | VP Commercial | Profile | |
| Michael MBA | Senior Commercial | Profile | |
| Arun Upadhyay | Chief Development | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ocugen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocugen. If investors know Ocugen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocugen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.20) | Revenue Per Share | Quarterly Revenue Growth (0.46) | Return On Assets | Return On Equity |
The market value of Ocugen Inc is measured differently than its book value, which is the value of Ocugen that is recorded on the company's balance sheet. Investors also form their own opinion of Ocugen's value that differs from its market value or its book value, called intrinsic value, which is Ocugen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocugen's market value can be influenced by many factors that don't directly affect Ocugen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ocugen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocugen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocugen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.